PEN Penumbra, Inc. logo

PEN Penumbra, Inc.

Healthcare
$329.20+0.00%OpenMarket Cap: $12.95B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

72.87

PEG

0.06

P/B

8.76

P/S

8.89

EV/EBITDA

60.69

DCF Value

$-99.82

FCF Yield

1.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

67.4%

Operating Margin

12.9%

Net Margin

11.8%

ROE

12.3%

ROA

9.0%

ROIC

9.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$374.8M$32.6M$
Q4 null$385.4M$47.3M$
FY null$1.40B$177.7M$
Q3 null$354.7M$45.9M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$369.83

Target (Median)

$374.00

Target Range

$335.00 - $388.00

2 Strong Buy2 Buy13 Hold0 Sell0 Strong Sell
CitigroupNeutral
2026-05-07
Evercore ISI GroupOutperform
2026-05-07
Evercore ISI GroupOutperform
2026-02-26
RBC CapitalSector Perform
2026-01-20
Canaccord GenuityHold
2026-01-20

Trading Activity

Insider Trades

View All
Elsesser Adamdirector, officer: CEO
SellThu May 21
Grewal Harpreetdirector
SellMon Apr 06
Yuen Maggieofficer: Chief Financial Officer
SellTue Mar 17
Shiu Lambertofficer: Chief Accounting Officer
SellTue Mar 17
Roberts Johannaofficer: EVP, Gen. Counsel & Secretary
SellTue Mar 17

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.73

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Peers